DCVA (Dutch Cardiovascular Alliance), RegMed XB, BioGeneration Ventures (BGV) and its fund FIRST proudly announce that their joint Thematic Tech Transfer (TTT) program has been awarded €10 million in funding by the Netherlands Enterprise Agency (RVO), on behalf of the Ministry of Economic Affairs.
The program aims to accelerate the translation of academic research into innovative companies focused on addressing chronic diseases.
Thanks to this funding, the successful TTT collaboration between DCVA, RegMed XB, and BGV/FIRST will not only be able to continue its impactful work, but also expand its scope, now with the active participation of four leading health foundations: the Dutch Kidney Foundation, Dutch Heart Foundation, Dutch Brain Foundation, and Dutch Diabetes Foundation. This expansion further strengthens the bridge between academic research, entrepreneurship, and societal impact, with the goal of bringing groundbreaking innovations to patients faster.
By combining training, mentoring, and access to funding, the program helps researchers make the leap from lab to market. The focus is on translational innovation: projects that are not only have exceptional science but also have the potential to deliver both clinical and societal impact.
The first TTT program (2020–2024) proved the impact of an integrated approach, supporting researchers nationwide in building business models, securing funding, and launching spin-offs. With 42 voucher projects and 14 start-ups created, 7 of which have already attracted investors, participating companies have raised over €43 million in follow-on investments. The new program builds on this success, accelerating the translation of scientific breakthroughs into solutions for chronic diseases.
With the launch of this new program, partner BioGeneration Ventures (BGV) is establishing FIRST II, a new pre-seed investment fund focused on chronic diseases. Building on the success of the original FIRST fund, which provided early financing to promising life sciences start-ups emerging from Dutch research, FIRST II will continue to bridge the gap between academic innovation and venture investment. Further details about the fund will be announced soon, follow RegMed XB on LinkedIn for udates.
Continuing the TTT program means that funding in the form of vouchers, will again be available for research projects with valorization potential in the field of chronic diseases.
Would you like to know more about the vouchers? Please contact one of the Impact Officers:
With a broad academic background in biomedical sciences, engineering, and business, Dominique works to bridge the gap between academia and industry. Dominique thrives on innovation and connecting with brilliant minds pushing the boundaries of human knowledge.
With an investor-like mindset, Dominique analyses research projects and helps develop a translational strategy for early-stage innovations to attract investments and progress toward the clinic.
Optional: In her free time, you will find Dominique performing with her band, or planning her next trip.
Why Dominique is passionate about our mission: Too often, great science does not reach the patient. To truly create an impact, academia and industry need to come together. At RegMed XB, we are building an ecosystem to facilitate just that.
Nick Beijer is a business developer at RegMed XB, where he works at the intersection of science, innovation, and strategic partnerships. He holds a PhD in biomedical engineering and has over a decade of experience in cell–biomaterial research. Before joining RegMed XB, Nick worked at the Dutch National Institute for Public Health and the Environment (RIVM), where he led multi-stakeholder research projects, advised the Ministry of Health, and supervised PhD candidates conducting research on next-generation medical implant safety assessment.
In his role at RegMed XB, Nick combines deep scientific expertise with a strong understanding of societal and policy dynamics. He identifies strategic opportunities for collaboration and translates complex stakeholder needs into concrete partnerships. He works closely with academic, clinical, public, and industrial partners to help shape initiatives that align with the organization’s long-term ambitions. Drawing on his experience in national research strategy and public-private collaboration, he focuses on building durable relationships and exploring sustainable business models that enable breakthroughs in regenerative medicine.
Nick is deeply driven by the mission of bringing affordable regenerative therapies to patients. He believes in the transformative potential of regenerative medicine, not only to treat, but to truly restore health. RegMed XB’s activities to accelerate this transition aligns closely with his personal motivation to create lasting, real-world impact for patients. He finds energy in enabling innovation by connecting people, organizations, and disciplines.
Luc Schoppink strives to fast-track innovation from lab to patient through translation of promising cardiology research into scalable ventures, with the aim to accelerate development and commercialization. Prior to his role of Impact Officer at DCVA, Luc worked in the role of Senior Consultant for Catalyze-Group, where he helped leading researchers and companies in Biotech, Medtech and Healthtech secure financing for ambitious R&D projects. Luc has a background in Biomedical- and Neurosciences, as well as a degree in Life Science based Management and Entrepreneurship. Today, Luc is dedicated to help promising research and innovation to reach its full potential.
Now you can contribute to keep our news section fresh and up-to date with relevant events and grants, research results and high impact publications related to REGMED XB’ Moonshots. Contributions can be sent to This email address is being protected from spambots. You need JavaScript enabled to view it.. Please submit the text in English and include a short title. We are looking forward to your input!
